Sugi Predict

Sugi Predict / Compounds / SCHEMBL84961

SCHEMBL84961

SCHEMBL84961

CC(C)C[C@H](NC(=O)[C@H](CCc1ccccc1)NC(=O)CN1CCCCC1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]1(C)CO1

nearest known ligand 0.89

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PSMB5 P28074 18/20 0.89
▸ PSMB2 P49721 4/20 0.89
▸ PSMB8 P28062 3/20 0.89
▸ PSMB10 P40306 3/20 0.89
▸ PSMB9 P28065 3/20 0.87
▸ PSMB1 P20618 2/20 0.86
▸ PSMB11 A5LHX3 1/20 0.86
▸ PSMD11 O00231 1/20 0.86
▸ PSMD12 O00232 1/20 0.86
▸ PSMD14 O00487 1/20 0.86
▸ PSMA7 O14818 1/20 0.86
▸ PSMD3 O43242 1/20 0.86
▸ CTSB P07858 1/20 0.86
▸ CYP3A4 P08684 1/20 0.86
▸ PSMC3 P17980 1/20 0.86
▸ CYP3A5 P20815 1/20 0.86
▸ CYP3A7 P24462 1/20 0.86
▸ PSMA1 P25786 1/20 0.86
▸ PSMA2 P25787 1/20 0.86
▸ PSMA3 P25788 1/20 0.86

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2633253 1.00 PSMB5 (0.89) PSMB5PSMB2PSMB8PSMB10PSMB9
SCHEMBL18871711 1.00 PSMB5 (0.89) PSMB5PSMB2PSMB8PSMB10PSMB9
SCHEMBL16104641 0.93 PSMB5 (0.78) PSMB5PSMB2PSMB8PSMB10PSMB9
SCHEMBL8267480 0.93 PSMB5 (0.78) PSMB5PSMB2PSMB8PSMB10PSMB9
Carfilzomib SCHEMBL23616374 0.93 PSMB5 (1.00) PSMB5PSMB2PSMB8PSMB10PSMB9
Carfilzomib SCHEMBL20825320 0.93 PSMB5 (1.00) PSMB5PSMB2PSMB8PSMB10PSMB9
SCHEMBL21156750 0.93 PSMB5 (0.85) PSMB5PSMB2PSMB8PSMB10PSMB9
Carfilzomib SCHEMBL25438395 0.93 PSMB5 (1.00) PSMB5PSMB2PSMB8PSMB10PSMB9
Carfilzomib SCHEMBL21036227 0.93 PSMB5 (1.00) PSMB5PSMB2PSMB8PSMB10PSMB9
Carfilzomib SCHEMBL21035430 0.93 PSMB5 (1.00) PSMB5PSMB2PSMB8PSMB10PSMB9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230293713-A1 ANTI-TM4SF1 ANTIBODY DRUG CONJUGATES AND METHODS OF USING SAME ANGIEX, INC. 2023-09-21 — — US disclosed
US-20170136085-A1 TARGETED THERAPEUTICS TVA (ABC), LLC 2017-05-18 — — US disclosed
US-8324174-B2 Compounds for enzyme inhibition ONYX THERAPEUTICS, INC. (US) 2012-12-04 — — US disclosed
US-20120277146-A1 Compounds For Enzyme Inhibition ONYX PHARMACEUTICALS INC. (US) 2012-11-01 — — US disclosed
US-8207297-B2 Compounds for enzyme inhibition ONYX THERAPEUTICS, INC. (US) 2012-06-26 — — US disclosed
US-8207124-B2 Compounds for enzyme inhibition ONYX THERAPEUTICS, INC. (US) 2012-06-26 — — US disclosed
US-8207125-B2 Compounds for enzyme inhibition ONYX THERAPEUTICS, INC. (US) 2012-06-26 — — US disclosed
US-8207126-B2 Compounds for enzyme inhibition ONYX THERAPEUTICS, INC. (US) 2012-06-26 — — US disclosed
US-8207127-B2 Compounds for enzyme inhibition ONYX TECHNOLOGIES, INC. (US) 2012-06-26 — — US disclosed
US-20120101048-A1 COMPOUNDS FOR ENZYME INHIBITION ONYX THERAPEUTICS, INC. (US) 2012-04-26 — — US disclosed
US-8129346-B2 Compounds for enzyme inhibition ONYX THERAPEUTICS, INC. (US) 2012-03-06 — — US disclosed
US-7491704-B2 Peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases, e.g., the chymotrypsin-like activity of the 20S proteasome; antiproliferative and antiinflammatory agents PROTEOLIX, INC. (US) 2009-02-17 — — US disclosed
US-7491704-B2 Peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases, e.g., the chymotrypsin-like activity of the 20S proteasome; antiproliferative and antiinflammatory agents PROTEOLIX, INC. (US) 2009-02-17 — — US disclosed
US-20080200398-A1 Compounds For Enzyme Inhibition PROTEOLIX, INC. (US) 2008-08-21 — — US disclosed
US-20080200398-A1 Compounds For Enzyme Inhibition PROTEOLIX, INC. (US) 2008-08-21 — — US disclosed
US-20070191284-A1 Peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases, e.g., the chymotrypsin-like activity of the 20S proteasome; antiproliferative and antiinflammatory agents PROTEOLIX, INC. (US) 2007-08-16 — — US disclosed
US-20070191284-A1 Peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases, e.g., the chymotrypsin-like activity of the 20S proteasome; antiproliferative and antiinflammatory agents PROTEOLIX, INC. (US) 2007-08-16 — — US disclosed
US-7232818-B2 Peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases, e.g., the chymotrypsin-like activity of the 20S proteasome; antiproliferative and antiinflammatory agents PROTEOLIX, INC. (US) 2007-06-19 — — US disclosed
US-7232818-B2 Peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases, e.g., the chymotrypsin-like activity of the 20S proteasome; antiproliferative and antiinflammatory agents PROTEOLIX, INC. (US) 2007-06-19 — — US disclosed
WO-2005105827-A2 COMPOUNDS FOR PROTEASOME ENZYME INHIBITION PROTEOLIX, INC. (US) 2005-11-10 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080200398-A1 Compounds For Enzyme Inhibition ANPEP, DNPEP, CPN1 PSMB5 24/4885PSMB2 14/4885PSMB8 46/4885
US-20170136085-A1 TARGETED THERAPEUTICS HSP90B1, HSP90AB1, CDC37 PSMB5 1248/4885PSMB2 1729/4885PSMB8 1540/4885
US-20120101048-A1 COMPOUNDS FOR ENZYME INHIBITION ANPEP, DNPEP, CPN1 PSMB5 24/4885PSMB2 14/4885PSMB8 46/4885
US-20120277146-A1 Compounds For Enzyme Inhibition ANPEP, DNPEP, CPN1 PSMB5 24/4885PSMB2 14/4885PSMB8 46/4885
US-20230293713-A1 ANTI-TM4SF1 ANTIBODY DRUG CONJUGATES AND METHODS OF USING SAME TM9SF4, TM9SF2, TM9SF3 PSMB5 1808/4885PSMB2 2456/4885PSMB8 2115/4885
US-20070191284-A1 Peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases, e.g., the chymotrypsin-like activity of the 20S proteasome; antiproliferative and antiinflammatory agents ANPEP, DNPEP, PSMB1 PSMB5 21/4885PSMB2 11/4885PSMB8 34/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.